Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.31 |
| ▸ | CDC25B | P30305 | 4/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.31 |
| ▸ | CDC25A | P30304 | 2/20 | 0.31 |
| ▸ | CMA1 | P23946 | 2/20 | 0.31 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.31 |
| ▸ | GLS | O94925 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30973730 | 1.00 | TMPRSS2 (0.39) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL27413244 | 0.95 | TMPRSS2 (0.37) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL30603734 | 0.94 | TMPRSS2 (0.40) | TMPRSS2 | |
| SCHEMBL24916988 | 0.93 | TMPRSS2 (0.39) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL25922652 | 0.92 | TMPRSS2 (0.39) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL30973797 | 0.92 | TMPRSS2 (0.36) | TMPRSS2 | |
| SCHEMBL30973712 | 0.92 | TMPRSS2 (0.36) | TMPRSS2 | |
| SCHEMBL30973736 | 0.92 | TMPRSS2 (0.38) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL30973764 | 0.92 | TMPRSS2 (0.38) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL30973779 | 0.91 | TMPRSS2 (0.38) | TMPRSS2PTPN1CDC25BPTPN2CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129963-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |